6/3/2021 8:23:10 AM
Teva Pharma Presents New Data From Clinical And Real-world Analyses Examining The Efficacy Of AJOVY For Migraine At ASH
6/3/2021 8:07:14 AM
Teva To Present Latest Data On AJOVY Injection At 2021 AHS Annual Meeting
5/17/2021 8:11:34 AM
Teva Pharma Announced The Launch Of It's Not OK – It's TD, A New National Television Advertising Campaign
5/3/2021 8:04:23 AM
Teva Announces New Data From 3-year Open-label Extension
study Of AUSTEDO Tablets
4/28/2021 7:04:07 AM
Teva Pharma Q1 GAAP Net Income Attributable To Teva $77 Mln Or
$0.07/Shr Vs $69 Mln Or $0.06/Shr Last Year
4/27/2021 8:04:53 AM
Teva To Highlight Long-term Efficacy, Safety, And Tolerability Data From The Pivotal ARM-TD And AIM-TD Clinical Trials
4/19/2021 8:07:23 AM
Teva Announces New Data From Clinical And Real-world Analyses Examining Efficacy Of AJOVY
4/15/2021 8:05:26 AM
Teva To Present New Analyses Of AJOVY Injection And AUSTEDO Tablets
3/4/2021 8:33:12 AM
EU Probes Possible Anticompetitive Conduct Of Teva In Relation To Multiple Sclerosis Medicine
2/26/2021 8:04:51 AM
Teva : New Study Published In Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments
2/10/2021 7:03:57 AM
Teva Q4 Revenues $4.454 Bln Flat With Last Year